Literature DB >> 16004853

Treatment of vascular dementia: evidence from epidemiologic studies.

Hee-Joon Bae1, Dilip K Pandey.   

Abstract

This article discusses the most relevant recent evidence on the prevention and treatment of vascular dementia from epidemiologic studies. Vascular dementia is the most common form of dementia after Alzheimer's disease and remains the only one that is preventable, although most of our knowledge about primary and secondary prevention of vascular dementia comes from direct extrapolation from works in stroke. Furthermore, at present there are no approved therapeutic agents for the treatment of vascular dementia. Recently, however, a number of reasonable studies on vascular dementia have been available. It is clear that rigorous control of vascular risk factors is important in primary and secondary prevention of vascular dementia, and perhaps in ameliorating its mild form. A rational therapeutic approach to the treatment of vascular dementia should be based on an understanding of its broad clinical spectrum and the diverse causes that may be responsive to currently available treatments.

Entities:  

Year:  2005        PMID: 16004853     DOI: 10.1007/s11936-005-0050-y

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  42 in total

Review 1.  Status of treatment of vascular dementia.

Authors:  H Lechner
Journal:  Neuroepidemiology       Date:  1998       Impact factor: 3.282

Review 2.  Status of risk factors for dementia associated with stroke.

Authors:  P B Gorelick
Journal:  Stroke       Date:  1997-02       Impact factor: 7.914

3.  Rivastigmine in subcortical vascular dementia: an open 22-month study.

Authors:  Rita Moretti; Paola Torre; Rodolfo M Antonello; Giuseppe Cazzato; Antonio Bava
Journal:  J Neurol Sci       Date:  2002-11-15       Impact factor: 3.181

4.  The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study.

Authors:  Françoise Forette; Marie-Laure Seux; Jan A Staessen; Lutgarde Thijs; Marija-Ruta Babarskiene; Speranta Babeanu; Alfredo Bossini; Robert Fagard; Blas Gil-Extremera; Tovio Laks; Zhanna Kobalava; Cinzia Sarti; Jaakko Tuomilehto; Hannu Vanhanen; John Webster; Yair Yodfat; Willem H Birkenhäger
Journal:  Arch Intern Med       Date:  2002-10-14

Review 5.  Conceptual background to vascular cognitive impairment.

Authors:  J V Bowler; R Steenhuis; V Hachinski
Journal:  Alzheimer Dis Assoc Disord       Date:  1999 Oct-Dec       Impact factor: 2.703

6.  Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology.

Authors:  J A Schneider; R S Wilson; J L Bienias; D A Evans; D A Bennett
Journal:  Neurology       Date:  2004-04-13       Impact factor: 9.910

7.  Donepezil in vascular dementia: a randomized, placebo-controlled study.

Authors:  D Wilkinson; R Doody; R Helme; K Taubman; J Mintzer; A Kertesz; R D Pratt
Journal:  Neurology       Date:  2003-08-26       Impact factor: 9.910

8.  Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

Authors:  G C Román; T K Tatemichi; T Erkinjuntti; J L Cummings; J C Masdeu; J H Garcia; L Amaducci; J M Orgogozo; A Brun; A Hofman
Journal:  Neurology       Date:  1993-02       Impact factor: 9.910

Review 9.  Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: overview of phase I and phase II clinical trials.

Authors:  R Mielke; H J Möller; T Erkinjuntti; B Rosenkranz; M Rother; B Kittner
Journal:  Alzheimer Dis Assoc Disord       Date:  1998       Impact factor: 2.703

Review 10.  Propentofylline for dementia.

Authors:  M Frampton; R J Harvey; V Kirchner
Journal:  Cochrane Database Syst Rev       Date:  2003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.